ROSGQ (Rosetta Genomics) Accounts Receivable: $0.47 Mil (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rosetta Genomics Accounts Receivable?

Rosetta Genomics ROSGQ Accounts Receivable is $0.47 Mil as of Jun. 2017.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Rosetta Genomics's accounts receivables for the quarter that ended in Jun. 2017 was $0.47 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Rosetta Genomics's Days Sales Outstanding for the quarter that ended in Jun. 2017 was 53.57.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Rosetta Genomics's Net-Net Working Capital per share for the quarter that ended in Jun. 2017 was $-1.32.

Rosetta Genomics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Rosetta Genomics's Days Sales Outstanding for the quarter that ended in Jun. 2017 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.472/1.608*91
=53.57

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Rosetta Genomics's accounts receivable are only considered to be worth 75% of book value:

Rosetta Genomics's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2017 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.325+0.75 * 0.472+0.5 * 0-5.108
-0-0)/2.588
=-1.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Rosetta Genomics Accounts Receivable Related Terms

Rosetta Genomics Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Accounts Receivable Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.22 0.34 3.63 2.85

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.02 3.63 3.37 2.85 0.47

Rosetta Genomics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of $0.47 Mil mean?
Rosetta Genomics (ROSGQ) has a Accounts Receivable of $0.47 Mil as of Jun. 2017. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Accounts Receivable too high?
Rosetta Genomics' current Accounts Receivable is $0.47 Mil.
How does Rosetta Genomics' Accounts Receivable compare to TEAR and IDTA?
Rosetta Genomics' Accounts Receivable of $0.47 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Diagnostics & Research company?
A good Accounts Receivable depends on the Medical Diagnostics & Research industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current Accounts Receivable is $0.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Accounts Receivable of $0.47 Mil. The current Accounts Receivable is $0.47 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Accounts Receivable is $0.47 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.